SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public offering of $100 million of...
Nektar Therapeutics Announces Pricing of $100 Million Public Offering
Seeking Alpha / 12 hours ago 1 Views
Comments